Last reviewed · How we verify
NCT06587399
Comparison of Manual Therapy Versus Radial Shock Waves in the Shoulder Pain Treatment
NA trial testing Manual therapy treatment in Shoulder Impingement in 88 participants. Currently enrolling.
15 September 2026
Quick facts
| Lead sponsor | University of Alcala |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 88 |
| Start date | 30 September 2024 |
| Primary completion | 15 September 2026 |
| Estimated completion | 15 September 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Manual therapy treatment
- Radial shock wave treatment
Conditions studied
- Shoulder Impingement — all drugs for Shoulder Impingement →
- Shoulder Pain — all drugs for Shoulder Pain →
Sponsor
University of Alcala
Who can join
Adults 18 to 80, any sex, with Shoulder Impingement or Shoulder Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Subacromial syndrome represents the third leading cause of pain in the general population. There is no clear pathophysiological explanation, nor a specific treatment. Manual therapy stands out as one of the reference treatments for this disease, however, it is complex to develop a specific protocol. On the other hand, shock waves have still not received adequate attention in the treatment of this pathology. The aim of this study will focus on using manual treatment using ischemic pressure, joint mobilizations and myofascial techniques in comparison to shock wave therapy to determine which is more effective. This study will be a randomized, single-blind clinical trial with third-party evaluation. In it 88 subjects suffering from subacromial syndrome will participate. 44 patients will receive treatment through manual therapy over 6 weeks and other 44 patients through low-med energy radial shock waves for 6 weeks. All subjects will complete their treatment with a 12-week home-based therapeutic exercise program. The main endpoint of the study will be pain measured using the visual analogue scale (VAS) in motion. Pain will also be assessed using the VAS scale at rest and overnight. The Spadi Spanish version questionnaire will be used, shoulder strength will be measured using a handheld dynamometer and the ranges of motion will be measured. Data will be measured before and one year after treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06587399
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Alcala trials
Trials by the same sponsor.
- NCT06599164 — Evaluation of Vastus Medialis Muscle Inhibition in Indoor Soccer Players With and Without ACL Injury · not yet recruiting
- NCT06587412 — Treatment of Lateral Epicondylalgia With Shock Waves · NA · recruiting
- NCT07333443 — Caffeine and Sport Climbing Performance · NA · completed
- NCT07015008 — Sleep and Maximal Fat Oxidation · NA · completed
- NCT06723821 — Noninvasive Neuromodulation in the Management of Post-COVID Musculoskeletal Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06587399 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alcala
- Last refreshed: 3 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06587399.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing